Clinical Trial Update: Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 safety evaluation study is recruiting patients with Aggressive NK-cell Leukemia to assess safety and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Nk-cell Leukemia

Snippet

Sponsor: Hiroshima University Hospital | Conditions: Aggressive NK Cell Leukemia | Phase 1, Phase 2 | Status: RECRUITING